|By PR Newswire||
|April 3, 2014 07:00 AM EDT||
EAST HANOVER, N.J., April 3, 2014 /PRNewswire/ -- Novartis announced today that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research (AACR), April 5-9, 2014 in San Diego, CA. The AACR annual meeting highlights basic, translational and clinical discoveries in oncology. The investigational compounds featured in these Novartis studies are directed at multiple molecular targets and pathways. Currently Novartis Oncology is exploring more than 30 targets involved in cancer1.
"Our research approach is driven by an understanding of cancers on a genomic level and developing therapies directed at those targets," said Alessandro Riva, President, Novartis Oncology ad interim and Global Head, Oncology Development and Medical Affairs. "The AACR presentations demonstrate the depth and breadth of our pipeline, which allows us to test various combinations at an early stage to target different pathways and mutations involved in cancer."
Among the data being presented are single agent and combination studies with key investigational compounds in the Novartis Oncology breast cancer development program, including an early phase study of the CDK4/6 inhibitor LEE011 and PI3K inhibitors BKM120 and BYL719. LEE011 and BKM120 are currently in Phase III and BYL719 is in Phase I trials for the treatment of advanced breast cancer.
In addition, preclinical data on ALK-inhibitor LDK378 (ceritinib) in ALK-positive non-small cell lung cancer (NSCLC) will be presented at the meeting. LDK378 was granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) in 2013 and is currently under review by the FDA.
Early data will be presented on three additional investigational compounds including BGJ398, a highly specific fibroblast growth factor receptor (FGFR) inhibitor that Novartis is exploring in a variety of FGFR-driven solid tumors. A Phase I study of BGJ398 provides the first clinical evidence of activity against cancers that are driven by dysregulation of the FGFR pathway. In addition, the first data on CGM097, a selective p53-Mdm2 inhibitor currently under evaluation in Phase I trials in patients with p53 wild type tumors, and EGF816, a mutant-selective third generation EGFR inhibitor that is entering Phase I trials, will be presented.
More than 50 abstracts involving Novartis investigational compounds will be presented at AACR, including:
- In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer (Abstract #4756; April 8, 4:05 p.m.)
- Loss of PTEN leads to clinical resistance to the PI3K inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure (Abstract #LB327; April 8, 3:50 p.m.; this abstract will also be presented as part of the official AACR press briefing on April 8 at 7:30 a.m.)
- The ALK inhibitor LDK378 overcomes crizotinib resistance in non-small cell lung cancer (Abstract #957; April 6, 4:05 p.m.)
- Combination CDK4/6 and ALK inhibition demonstrates on-target synergy against neuroblastoma (Abstract #1000; April 6, 4:35 p.m.)
- The Mdm2 inhibitor NVP-CGM097 enhances the anti-tumor activity of NVP-LDK378 in ALK mutant neuroblastoma models (Abstract #2929; April 7, 4:35 p.m.)
- Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors (Abstract #CT326; April 8, 10:50 a.m.; this abstract will also be presented as part of the official AACR press briefing on April 8 at 7:30 a.m.)
- Pre-clinical characterization and clinical development of NVP-CGM097, a highly selective and optimized small-molecule inhibitor of p53-Mdm2 protein-protein interaction (Abstract #ED37-01; April 5, 3:15 p.m.)
- Discovery of NVP-CGM097 as a novel Mdm2 inhibitor (Abstract #DDT01-01; April 6, 1:00 p.m.)
- A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models (Abstract #2909; April 7, 3:00 p.m.)
- The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma (Abstract #5466; April 9, 8:00 a.m.)
- EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC (Abstract #1733; April 7, 2014, 8:00 a.m.)
- In vitro characterization of EGF816, a third-generation mutant-selective EGFR inhibitor (Abstract #1734; April 7, 8:00 a.m.)
About LEE011, BKM120, BYL719, LDK378, BGJ398, CGM097, LGX818 and EGF816
Because these are investigational compounds, the safety and efficacy profiles of LEE011, BKM120, BYL719, LDK378, BGJ398, CGM097, LGX818 and EGF816 have not yet been established. Access to these investigational compounds is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the treatments. Because of the uncertainty of clinical trials, there is no guarantee that LEE011, BKM120, BYL719, LDK378, BGJ398, CGM097, LGX818 and EGF816 will ever be commercially available anywhere in the world. The prefix NVP before a code name is the same compound as the code name alone.
LEE011 was discovered as part of a drug discovery collaboration between the Novartis Institutes for BioMedical Research and Astex Pharmaceuticals.
The BYL719 and BGJ398 abstracts will be presented as part of an official AACR press briefing on Tuesday April 8 at 7:30 a.m. PT in room 15B of the San Diego Convention Center. Reporters unable to attend in person can dial in by calling 1 (866) 297-6395 (US/Canada) or 1 (847) 944-7317 (International), confirmation code: 36855822.
The foregoing release contains forward-looking statements that can be identified by words such as "pipeline," "investigational," "will," "exploring," "being presented," "leads to," "predicts," "yet," "designed," "potential," or similar terms, or by express or implied discussions regarding potential marketing authorizations for LEE011, BKM120, BYL719, LDK378, BGJ398, CGM097, LGX818, EGF816 or any other Novartis compounds to be presented at the AACR annual meeting, or regarding potential future revenues from such compounds. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that any of such compounds will be approved for sale in any market where such compounds have been submitted, or will be submitted or approved for sale in any additional markets, or at any particular time. Nor can there be any guarantee that such compounds will be commercially successful in the future. In particular, management's expectations regarding such compounds could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative medicines aimed at improving patients' lives. We offer a broad range of medicines for cancer, cardiovascular disease, endocrine disease, inflammatory disease, infectious disease, neurological disease, organ transplantation, psychiatric disease, respiratory disease and skin conditions. The company's mission is to improve people's lives by pioneering novel healthcare solutions.
Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 136,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
- American Association of Cancer Research. AACR 2014 Annual Meeting Program. Available at: http://www.abstractsonline.com/plan/start.aspx?mkey=%7B6FFE1446-A164-476A-92E7-C26446874D93%7D
Novartis Media Relations
Novartis Media Relations
+1 212 830 2465 (direct)
+1 862 778 2836
+1 862 579 8456 (mobile)
+1 862 210 5328
e-mail: [email protected]
SOURCE Novartis Pharmaceuticals Corporation
One of the bewildering things about DevOps is integrating the massive toolchain including the dozens of new tools that seem to crop up every year. Part of DevOps is Continuous Delivery and having a complex toolchain can add additional integration and setup to your developer environment. In his session at @DevOpsSummit at 18th Cloud Expo, Miko Matsumura, Chief Marketing Officer of Gradle Inc., will discuss which tools to use in a developer stack, how to provision the toolchain to minimize onboa...
Feb. 12, 2016 09:00 PM EST Reads: 131
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed...
Feb. 12, 2016 06:00 PM EST Reads: 402
Companies can harness IoT and predictive analytics to sustain business continuity; predict and manage site performance during emergencies; minimize expensive reactive maintenance; and forecast equipment and maintenance budgets and expenditures. Providing cost-effective, uninterrupted service is challenging, particularly for organizations with geographically dispersed operations.
Feb. 12, 2016 06:00 PM EST
When building large, cloud-based applications that operate at a high scale, it’s important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. “Fly two mistakes high” is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Lee...
Feb. 12, 2016 04:45 PM EST
DevOps is not just last year’s buzzword. Companies with DevOps practices are 2.5x more likely to exceed profitability, market share, and productivity goals. But how do you enable high performance? What can you do right now to start? Find out from DevOps experts including Gene Kim, co-author of "The Phoenix Project," and the Dynatrace Center of Excellence.
Feb. 12, 2016 04:30 PM EST
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
Feb. 12, 2016 04:30 PM EST Reads: 191
SYS-CON Events announced today that Column Technologies will exhibit at SYS-CON's @DevOpsSummit at Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Established in 1998, Column Technologies is a global technology solutions provider with over 400 employees, headquartered in the United States with offices in Canada, India, and the United Kingdom. Column Technologies provides “Best of Breed” technology solutions that automate the key DevOps principal...
Feb. 12, 2016 04:15 PM EST
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 ad...
Feb. 12, 2016 04:15 PM EST Reads: 428
Join us at Cloud Expo | @ThingsExpo 2016 – June 7-9 at the Javits Center in New York City and November 1-3 at the Santa Clara Convention Center in Santa Clara, CA – and deliver your unique message in a way that is striking and unforgettable by taking advantage of SYS-CON's unmatched high-impact, result-driven event / media packages.
Feb. 12, 2016 03:00 PM EST
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management...
Feb. 12, 2016 02:15 PM EST Reads: 451
There will be new vendors providing applications, middleware, and connected devices to support the thriving IoT ecosystem. This essentially means that electronic device manufacturers will also be in the software business. Many will be new to building embedded software or robust software. This creates an increased importance on software quality, particularly within the Industrial Internet of Things where business-critical applications are becoming dependent on products controlled by software. Qua...
Feb. 12, 2016 02:15 PM EST
As someone who has been dedicated to automation and Application Release Automation (ARA) technology for almost six years now, one of the most common questions I get asked regards Platform-as-a-Service (PaaS). Specifically, people want to know whether release automation is still needed when a PaaS is in place, and why. Isn't that what a PaaS provides? A solution to the deployment and runtime challenges of an application? Why would anyone using a PaaS then need an automation engine with workflow ...
Feb. 12, 2016 01:45 PM EST Reads: 232
With an estimated 50 billion devices connected to the Internet by 2020, several industries will begin to expand their capabilities for retaining end point data at the edge to better utilize the range of data types and sheer volume of M2M data generated by the Internet of Things. In his session at @ThingsExpo, Don DeLoach, CEO and President of Infobright, will discuss the infrastructures businesses will need to implement to handle this explosion of data by providing specific use cases for filte...
Feb. 12, 2016 01:00 PM EST Reads: 230
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies adopt disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advanced analytics, and DevO...
Feb. 12, 2016 12:30 PM EST Reads: 266
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Avere delivers a more modern architectural approach to storage that doesn’t require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbuilding of data centers ...
Feb. 12, 2016 12:30 PM EST Reads: 108